Related to these pro-inflammatory events triggered by FHR-3, we chimerized our anti-FHR-3 antibody RETC-2 and hypothesized that RETC-2-ximab might serve as a new therapeutic approach for treatment of degenerated eye diseases such as AMD. This evidence concerns the gene CFHR3 and age-related macular degeneration.